Drug Profile
Research programme: cancer therapeutics - Turning Point Therapeutics
Alternative Names: ALK inhibitors - Turning Point TherapeuticsLatest Information Update: 22 Aug 2022
Price :
$50
*
At a glance
- Originator TP Therapeutics
- Developer Turning Point Therapeutics
- Class Antineoplastics; Macrocyclic compounds; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; Proto-oncogene protein pp60(c-src) inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours